Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic ...

Cough is a crucial protective reflex that helps protect the lungs and airways. However, when cough becomes chronic and ...

AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal ...

In a report released yesterday, Faisal Khurshid from Leerink Partners maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report), ...

Gefapixant, a novel oral medication, has shown promise in clinical trials for patients with refractory chronic cough and unexplained chronic cough. In two large phase 3 trials, COUGH-1 and COUGH-2 ...

For more than a decade Bethan has been living with a chronic refractory cough, the medical term for a condition with no obvious cause. It's a common complaint thought to affect one in ten of the ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.